This video is featured in the 2024 ESMO Annual Meeting Insights Hub

2024 ESMO Annual Meeting Insights Hub
P

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01

By 2024 ESMO Annual Meeting Insights Hub FEATURING Paolo Tarantino
By 2024 ESMO Annual Meeting Insights Hub FEATURING Paolo Tarantino
772 views
September 24, 2024

Chapters

NATALEE Trial & Adjuvant Ribociclib Outcomes

00:00

DESTINY-Breast12: T-DXd in HER2-Positive Cancer

04:12

KEYNOTE-522: Pembrolizumab's Survival Impact

06:46

CAPitello-290: AKT Inhibition in TNBC

09:11

ICARUS-Breast01: HER3-DXd Efficacy & Safety

11:45

Comments 0
Login to view comments. Click here to Login

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

2024 ESMO Annual Meeting Insights Hub: Breast Videos

06:23

New

ESMO 2024 Insights: Quality-Adjusted Time Without Symptoms or Toxici…

2024 ESMO Annual Meeting Insights Hub

A. Brufsky

09:23

New

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-…

2024 ESMO Annual Meeting Insights Hub

P. Fasching

54 views
05:07

New

ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine i…

2024 ESMO Annual Meeting Insights Hub

S. Kim

39 views
View All

Related Videos

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.2K views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.2K views
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.4K views
11:31

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views
12:35

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.5K views
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

617 views
03:40

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views
17:39

2023 Menopause Update

Yale School of Medicine

M. Minkin

9.1K views
08:49

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

791 views
17:50

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views
06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
05:43

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

977 views
36:18

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views
03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
28:36

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials Inclu…

Insights from 2023 ASCO® Annual Meeting

H. Rugo, K. Jhaveri

4.8K views
AUTOPLAY